Novartis/HGS' Albuferon ACHIEVEs Non-inferiority To Pegasys For Hepatitis C
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Solid results from the first of two key Phase III trials for Novartis/Human Genome Sciences’ hepatitis C candidate Albuferon (albinterferon alfa-2b) reduce the pressure by alleviating an earlier pulmonary safety concern, but the question remains whether quality of life and dosing benefits are enough for Albuferon to make headway in the interferon market.
You may also be interested in...
Follow-On Biologics Market Unfolding: Big Pharma Signals An Interest
Large pharmaceutical and biotechnology companies will start openly developing follow-on biologics once Congress passes legislation authorizing an abbreviated approval pathway, Cowen & Co. analyst Ken Cacciatore predicted
HGS Cuts High Dose Albuferon In Phase III After Increased Pulmonary Events
Lower 900 mcg dose of albinterferon alfa-2b is on track for hepatitis C filing in fall 2009, Human Genome Sciences says.
Human Genome Sciences Achieves Milestone For Albuferon Phase II Completion
HGS expects data from ACHIEVE pivotal program by spring 2009; global filings by fall 2009.